Attapon Cheepsattayakorn^1,3*, Ruangrong Cheepsattayakorn² and Porntep Siriwanarangsun³

¹10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: January 25, 2023; Published: February 01, 2023

Particularly, the Omicron and its subvariants [1], such as BA.4, BA.5, BQ.1, BQ.1.1, BF.7, XBB, and XBB.1 [2] have triggered COVID-19 pandemic waves around the world [1]. In January and February 2022, a containing 15 µg of mRNA directed against the SARS-CoV-2 (COVID-19) ancestral strain and 15 µg directed against BA.1 bivalent COVID-19 vaccine was produced by Pfizer-BioNTech, whereas 25 µg of mRNA directed against the same two strains was produced by Moderna [2]. On August 31, 2022, United States Food and Drug Administration (US FDA) authorized the use of Pfizer-BioNTech (Figure 1) [1] and Moderna (Figure 2) [1] bivalent COVID-19 vaccines as a single booster dose in persons 12 years of age and above and in persons 18 years of age and above, respectively [3], whereas Barouch., et al. revealed no impression of CD4+ or CD8+ T-cell different response between bivalent-booster group and monovalent-booster group [2].

References

1. Biosystem Acro. “Polyvalent, bivalent, and variant COVID-19 vaccines” (2023).
2. Offit PA. “Bivalent COVID-19 vaccines-a cautionary tale”. The New England Journal of Medicine (2023).
3. United States Food and Drug Administration (2022).

Citation

Citation: Attapon Cheepsattayakorn., et al. “Bivalent COVID-19 Vaccines". Acta Scientific Microbiology 6.3 (2023): 01-02.

Copyright

Copyright: © 2022 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.